Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

advanceCOR GmbH

Home Clinical Trial Sponsors and OrganizationsadvanceCOR GmbH

advanceCOR GmbH

ACTIVE

Fraunhoferstr. 9a, Planegg, Bayern, Germanywww.advancecor.comHolding1–10 employeesEstablished: 2012-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

4

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2012

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

75.0%

Phase 2

1

25.0%

Trial Status Distribution

Active, not recruiting

2

50.0%

Completed

2

50.0%

Clinical Trials

Trials sponsored by this organization (4)

REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS

Active, not recruiting

Aug 2013150 participants

Revacept in Symptomatic Carotid Stenosis

Mar 2013158 participants

REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROUPS

Active, not recruiting

Nov 2011150 participants

Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion

Mar 200630 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials4
Approvals
News

Back to Organizations